Spruce Biosciences Taps Rare Disease Veteran as CMO Ahead of Key Regulatory Milestone — Spruce Biosciences, Inc.

Event summary

Spruce Biosciences appointed Adrian Quartel, M.D., as Chief Medical Officer effective July 27, 2026.
Dr. Quartel brings 25 years of experience in rare disease drug development, including roles at BioMarin and Zevra Therapeutics.
Spruce plans to file a Biologics License Application (BLA) for tralesinidase alfa enzyme replacement therapy (TA-ERT) in Q4 2026.
Dr. Quartel received an inducement award of 13,000 restricted stock units (RSUs), vesting over four years.

The big picture

Spruce Biosciences is positioning itself for a critical regulatory milestone with the appointment of Adrian Quartel as CMO. His background in launching enzyme replacement therapies aligns with Spruce's goal of bringing TA-ERT to market, addressing a significant unmet need in pediatric neurodegenerative disorders. The move underscores the company's focus on rare disease treatments and its strategic push toward commercialization.

What we're watching

Regulatory Momentum: Whether Spruce can successfully file and gain approval for TA-ERT by Q4 2026, marking a potential first disease-modifying treatment for Sanfilippo Syndrome Type B.
Leadership Impact: How Dr. Quartel's extensive experience in rare disease drug development will influence Spruce's clinical and regulatory strategy ahead of the BLA filing.
Market Readiness: The pace at which Spruce can prepare for a potential commercial launch, given the lack of current FDA-approved therapies for MPS IIIB.